The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Open accessAbstract
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–256 of 256
Battram, A. M., Bachiller, M., López, V., de Larrea, C. F., Urbano-Ispizúa, Á., & Martín-Antonio, B. (2021) · Cancers · doi:10.3390/cancers13143534 · Cited by 70
Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia
Maciocia, P. M., Wawrzyniecka, P. A., Maciocia, N., Burley, A., Karpanasamy, T., Devereaux, S., Hoekx, M., O’Connor, D., León, T. E., Rapoz-D’Silva, T., et al. (2022) · Blood · doi:10.1182/blood.2021013648 · Cited by 70
Gómez‐Nicola, D., Valle‐Argos, B., & Nieto‐Sampedro, M. (2009) · Glia · doi:10.1002/glia.20920 · Cited by 67
Wenthe, J., Naseri, S., Labani‐Motlagh, A., Enblad, G., Wikstrom, K. I., Eriksson, E., Loskog, A., & Lövgren, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02895-7 · Cited by 66
Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs
Nguyen, D., Ball, E. D., & Varki, A. P. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.03.003 · Cited by 64
Li, S., Xue, L., Wang, M., Qiang, P., Xu, H., Zhang, X., Kang, W., You, F., Xu, H., Wang, Y., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198567 · Cited by 64
Self-citationAlabanza, L. M., Xiong, Y., Vu, B. K., Webster, B., Wu, D., Hu, P., Zhu, Z., Dropulić, B., Dash, P., & Schneider, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832645 · Cited by 64
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients
Wang, D., Zeng, C., Xu, B., Xu, J., Wang, J., Jiang, L., Wang, Q., Li, C., Wang, N., Huang, L., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0274-9 · Cited by 60
Self-citationDeng, H., Liu, M., Yuan, T., Zhang, H., Cui, R., Li, J., Yuan, J., Wang, X., Wang, Y., & Deng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720571 · Cited by 59
Self-citationAutio, M. I., Leivonen, S., Brück, O. E., Karjalainen‐Lindsberg, M., Pellinen, T. S., & Leppä, S. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3140 · Cited by 59
Direct control of CAR T cells through small molecule-regulated antibodies
Park, S., Pascua, E., Lindquist, K. C., Kimberlin, C. R., Deng, X., Mak, Y. S. L., Melton, Z., Johnson, T., Lin, R., Boldajipour, B. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20671-6 · Cited by 58
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Wenthe, J., Naseri, S., Hellström, A.-C., Jernberg‐Wiklund, H., Eriksson, E., & Loskog, A. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0176-9 · Cited by 57
Štach, M., Ptáčková, P., Mucha, M., Musil, J., Klener, P., & Otáhal, P. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.08.005 · Cited by 57
Deng, T., Tang, C., Zhang, G., & Wan, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03428-x · Cited by 57
Holthof, L. C., van der Schans, J. J., Katsarou, A., Poels, R., Gelderloos, A. T., Drent, E., Veen, S. E. V. H.-V., Li, F., Zweegman, S., van de Donk, N. W. C. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2188 · Cited by 57
Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., Leng, Y., Ren, A., Liu, X., Zhang, Z., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01178-z · Cited by 54
Wang, D., Mao, X., Que, Y., Xu, M., Cheng, Y., Huang, L., Wang, J., Xiao, Y., Wang, W., Hu, G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00563-8 · Cited by 54
Self-citationHMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation
Dulmovits, B. M., Tang, Y., Papoin, J., He, M., Li, J., Yang, H., Addorisio, M. E., Kennedy, L. P., Khan, M., Brindley, E. C., et al. (2022) · Blood · doi:10.1182/blood.2021012048 · Cited by 53
Lin, G., Zhang, Y., Yu, L., & Wu, D. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11847 · Cited by 52
Han, L., Zhou, J., Zhou, K., Zhu, X., Zhao, L., Fang, B., Yin, Q., Wei, X., Zhou, H., Li, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000927 · Cited by 51
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL
Zanetti, S. R., Velasco-Hernández, T., Gutiérrez‐Agüera, F., Diaz, V. M., Romecín, P. A., Roca-Ho, H., Sánchez‐Martínez, D., Tirado, N., Baroni, M. L., Petazzi, P., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.033 · Cited by 51
Voorhees, T. J., Zhao, B., Oldan, J. D., Hucks, G., Khandani, A. H., Dittus, C. E., Smith, J. K., Morrison, J. K., Cheng, C. J. A., Ivanova, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005385 · Cited by 51
Que, Y., Xu, M., Xu, Y., Almeida, V. D. F., Zhu, L., Wang, Z., Wang, Y., Liu, X., Jiang, L., Wang, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755866 · Cited by 50
Self-citationHu, Y., Wang, J., Wei, G., Yu, J., Luo, Y., Shi, J., Wu, W., Zhao, K., Xiao, L., Zhang, Y., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0403-2 · Cited by 49
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity
Wei, J., Zhao, J., Han, M., Meng, F., & Zhou, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000862 · Cited by 48
Guo, Z., Tu, S., Yu, S., Wu, L., Pan, W., Chang, N., Zhou, X., Song, C., Li, Y., & He, Y. (2021) · Cancer Science · doi:10.1111/cas.14799 · Cited by 46
Liu, M., Deng, H., Mu, J., Li, Q., Pu, Y., Jiang, Y., Deng, Q., & Qian, Z. (2021) · Cancer Science · doi:10.1111/cas.14915 · Cited by 46
Yang, Q., Hao, J., Chi, M., Wang, Y., Xin, B., Huang, J., Lu, J., Li, J., Sun, X., Li, C., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2055703 · Cited by 46
Healing after death: antitumor immunity induced by oncolytic adenoviral therapy
Jiang, H., & Fueyo, J. (2014) · Oncoimmunology · doi:10.4161/21624011.2014.947872 · Cited by 44
Wang, J., Deng, Q., Jiang, Y., Zhang, R., Zhu, H., Meng, J., & Li, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10783 · Cited by 43
Ikezoe, T. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02992-w · Cited by 43
Asimakopoulos, F. A., Hope, C. L., Johnson, M. G., Pagenkopf, A. C., Gromek, K., & Nagel, B. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr1116-468r · Cited by 42
Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies
Wada, M., Zhang, H., Liu, F., Feng, J., Tse, C. O., Zhang, W., Chen, Q., Sha, S., Cao, Y., Chen, K. H., et al. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09937-9 · Cited by 40
Self-citationShao, M., Yu, Q., Teng, X., Guo, X., Wei, G., Xu, H., Cui, J., Chang, A. H., Hu, Y., & Huang, H. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01226-9 · Cited by 40
Zhao, G., Wei, R., Feng, L., Wu, Y., He, F., Xiao, M., & Zhi, C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02959-8 · Cited by 40
Schubert, M., Dietrich, S., Stilgenbauer, S., Schmitt, A., Pavel, P., Kunz, A. B., Bondong, A., Wegner, M., Stadtherr, P., Jung, S., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.025 · Cited by 37
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
Sanchez, L. J., Dardac, A., Madduri, D., Richard, S., & Richter, J. R. (2021) · Therapeutic Advances in Hematology · doi:10.1177/2040620721989585 · Cited by 37
Meyer, J.-E., Loff, S., Dietrich, J., Spehr, J., Jiménez, G. J., Bonin, M. V., Ehninger, G., Cartellieri, M., & Ehninger, A. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1945804 · Cited by 35
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL
Tan, Y., Cai, H., Li, C., Deng, B., Song, W., Ling, Z., Hu, G., Yang, Y., Niu, P., Meng, G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00465-9 · Cited by 34
Zhu, H., Deng, H., Mu, J., Lyu, C., Jiang, Y., & Deng, Q. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s312904 · Cited by 32
Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges
Dhakal, B., Hari, P., Usmani, S. Z., & Hamadani, M. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01023-w · Cited by 30
Wang, S., Sellner, L., Wang, L., Sauer, T., Neuber, B., Gong, W., Stock, S., Ni, M., Yao, H., Kleist, C., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.8121 · Cited by 30
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
Workenhe, S. T., & Mossman, K. L. (2013) · OncoImmunology · doi:10.4161/onci.27138 · Cited by 28
Li, P., Zhou, L., Ye, S., Zhang, W., Wang, J., Tang, X., Liu, J., Xu, Y., Qian, W., & Liang, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638678 · Cited by 28
Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
Liu, M., Wang, X., Li, Z., Zhang, R., Mu, J., Jiang, Y., Deng, Q., & Sun, L. (2020) · Cancer Science · doi:10.1111/cas.14638 · Cited by 27
Adoptive T cell therapy of solid tumors: time to team up with immunogenic chemo/radiotherapy
Pocaterra, A., Catucci, M., & Mondino, A. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.10.004 · Cited by 26
Chari, A., Vogl, D. T., Jagannath, S., Jasielec, J. K., Unger, T. J., DeCastro, A., Shah, J. J., Kauffman, M. G., Shacham, S., & Jakubowiak, A. J. (2020) · British Journal of Haematology · doi:10.1111/bjh.16550 · Cited by 24
Khan, M. M., Liu, Y., Khan, M. E., Gilman, M. L., Khan, S. T., Bromberg, M. E., & Colman, R. W. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00825.2009 · Cited by 23
Zhang, W.-Y., Liu, Y., Wang, Y., Wang, C.-M., Yang, Q.-M., Zhu, H.-L., & Han, W.-D. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.54 · Cited by 23
Zhang, R., Deng, Q., Jiang, Y., Zhu, H., Wang, J., & Zhao, M. (2019) · Oncology Reports · doi:10.3892/or.2019.7096 · Cited by 22
Kenderian, S. S., Ruella, M., Shestova, O. E., Klichinsky, M., Kim, M. Y., Porter, D. L., June, C. H., & Gill, S. I. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.11.291 · Cited by 19
Dong, R., Jiang, S., Chen, Y., Ma, Y., Sun, L., Xing, C., Zhang, S., & Yu, K. (2021) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2021.0057 · Cited by 17
Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
Xing, L., Wang, Y., Liu, H., Gao, S., Shao, Q., Yue, L., Liu, Z., Wang, H., Shao, Z., & Fu, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.798352 · Cited by 16
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
Oriol, A., Abril, L., Torrent, A., Ibarra, G., & Ribera, J. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211019622 · Cited by 15
Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function
Qi, C., Tian, S., Wang, J., Ma, H., Qian, K., & Zhang, X. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.988340 · Cited by 10
Self-citationYang, C., Lei, W., Xie, H.-Q., Wu, G., Wei, J., Liang, A., & Qian, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s280535 · Cited by 6
Metadata
- Authors
- Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-06-10
- Volume
- 13
- Pages
- 927153-927153
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4281961745
- Cited by
- 396
- References
- 256
- FWCI
- 28.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.